Helicobacter Pylori
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. May 14, 2005; 11(18): 2726-2732
Published online May 14, 2005. doi: 10.3748/wjg.v11.i18.2726
Table 1 Characteristics of RBC-containing triple and quadruple therapies.
RefsCombination regimensDoseTreatment durationEradication rate (ITT)
P
PUD
NUD
N/T.N (%)N/T.N (%)
Triple therapies
RBCCA
6RBC/Cla/Amo400 mg b.i.d./500 mg b.i.d./1 g b.i.d.7 d20/23 (86.96)18/22 (81.8)
15RBC/Cla/Amo400 mg b.i.d./500 mg b.i.d./1 g b.i.d.7 d13/18 (72.2)48/57 (84.2)
16RBC/Cla/Amo400 mg b.i.d./500 mg b.i.d./1 g b.i.d.7 d19/23 (82.6)66/76 (86.8)
Others52/64 (81.3)132/155 (85.2)1
13RBC/Cla/Tin400 mg b.i.d./500 mg b.i.d./500 mg b.i.d.5 d20/27 (74.1)23/39 (58.97)0.32
9RBC/Cla/Tin400 mg b.i.d./500 mg b.i.d./500 mg b.i.d.5 d6/9 (66.7)9/12 (75)0.95
16RBC/Cla/Met400 mg b.i.d./500 mg b.i.d./400 mg b.i.d.7 d20/21 (95.2)69/78 (88.5)0.61
16RBC/Met/Tet400 mg b.i.d./400 mg b.i.d./1 g b.i.d.7 d38/46 (82.6)43/54 (79.6)0.9
14RBC/Fur/Tet350 mg b.i.d./100 mg b.i.d./500 mg b.i.d.7 d20/24 (83.3)31/36 (86.1)0.94
14RBC/Fur/Amo350 mg b.i.d./100 mg b.i.d./1 g b.i.d.7 d15/19 (78.95)34/41 (82.9)0.99
Quadruple therapy
6RBC/Cla/Amo/Met400 mg b.i.d./400 mg b.i.d./1 g b.i.d./500 mg b.i.d.5 d174/174 (100)62/71 (87.3)<0.05
Table 2 Characteristics of bismuth- or PPI-based quadruple therapies.
RefsCombination regimensDoseTreatment durationEradication rate (ITT)
P
PUD
NUD
N/T.N (%)N/T.N (%)
17CBS/Met/Tet/Lan120 mg ×8/250 mg ×8/250 mg ×8/30 mg b.i.d.1d22/33 (66.7)5/13 (38.5)0.16
17CBS/Met/Tet/Lan120 mg ×8/250 mg ×8/250 mg ×8/30 mg b.i.d.2 d26/35 (74.3)20/40 (50)0.06
13Amo/Cla/Tin/Ome1 g b.i.d./500 mg b.i.d./500 mg b.i.d./20 mg b.i.d.5 d1230/31 (96.8)31/34 (91.2)0.68
18Bis/Met/Tet/Lan120 mg q.i.d./400 mg t.i.d./500 mg q.i.d./30 mg q.d.7 d91/101 (90.1)107/118 (90.7)0.93
19Bis/Met/Tet/Ome120 mg q.i.d./400 mg t.i.d./500 mg q.i.d./30 mg q.d.10 d53/57 (93)46/49 (93.9)0.84
8Bis/Met/Tet/Ome120 mg q.i.d./500 mg t.i.d./500 mg q.i.d./20 mg b.i.d.14 d9/11 (81.8)8/13 (61.5)0.53
Table 3 Characteristics of triple therapies consisting of a PPI, clarithromycin and amoxicillin.
RefsCombination regimensDoseTreatmentduration (d)Eradication rate (ITT)
P
PUD
NUD
N/T.N (%)N/T.N (%)
22Ome/Cla/Amo20 mg b.i.d./500 mg b.i.d./1 g b.i.d.7134/161 (83.2)34/42 (81)
7Ome/Cla/Amo20 mg b.i.d.1/500 mg b.i.d./1 g b.i.d.760/65 (92.3)30/50 (60)
9PPI/Cla/AmoPPI b.i.d./500 mg b.i.d./1 g b.i.d .727/34 (79.4)15/21 (71.4)
11Rab/Cla/Amo20 mg b.i.d./500 mg b.i.d./1 g b.i.d.7101/135 (74.8)288/392 (73.5)
20Pan/Cla/Amo40 mg b.i.d./500 mg b.i.d./1 g b.i.d.727/29 (93.1)13/19 (68.4)
27Rab/Cla/Amo20 mg b.i.d./500 mg b.i.d./1 g b.i.d.782/101 (81.2)68/93 (73)
431/525 (82.1)448/617 (72.6)2
10Ome/Cla/Amo40 mg b.i.d./800 mg b.i.d./2 g b.i.d.787/98 (88.8)6/6 (100)0.388
10Ome/Cla/Amo40 mg b.i.d./1.6 g b.i.d./2 g b.i.d.751/51 (100)49/50 (98)0.313
8Lan/Cla/Amo30 mg b.i.d./500 mg b.i.d./1 g b.i.d.1013/13 (100)65/71 (91.6)
21Ome/Cla/Amo20 mg b.i.d./500 mg b.i.d./1 g b.i.d.1063/96 (65.6)20/27 (74.1)
27Rab/Cla/Amo20 mg b.i.d./500 mg b.i.d./1 g b.i.d.1075/97 (77.3)78/99 (78.8)
27Ome/Cla/Amo20 mg b.i.d./500 mg b.i.d./1 g b.i.d.1077/103 (74.8)68/103 (73.1)
231/309 (74.8)231/300 (77)3
Table 4 Characteristics of triple therapies consisting of a PPI, metronidazole and clarithromycin or amoxicillin.
RefsCombination regimensDoseTreatment durationEradication rate (ITT)
P
PUD
NUD
N/T.N (%)N/T.N (%)
23Pan/Met/Cla40 mg q.d./400 mg b.i.d./250 mg b.i.d.7 d54/65 (83.1)21/24 (87.5)0.613
23Pan/Met/Cla40 mg b.i.d./400 mg b.i.d./250 mg b.i.d.7 d54/64 (84.4)18/22 (81.8)0.781
24Ome/Met/Cla40 mg q.d./500 mg b.i.d./250 mg b.i.d.7 d15/19 (78.95)5/6 (83.3)0.819
25Pan/Met/Amo40 mg b.i.d./500 mg b.i.d./1 g b.i.d.7 d14/19 (73.7)7/11 (63.6)0.569
26Ome/Met/Amo40 mg q.d./400 mg t.i.d.1/750 mg b.i.d.14 d22/27 (81.5)22/37 (59.5)0.063